IPP Bureau
Everest Organics develops API for molnupiravir
By IPP Bureau - October 12, 2021
The drug is being developed at lab scale for the first-line of treatment of Covid-19
.jpg "Covaxin for kids gets nod, final approval awaited")
Covaxin for kids gets nod, final approval awaited
By IPP Bureau - October 12, 2021
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Intas launches the world's first SB-100mg Itraconazole
By IPP Bureau - October 12, 2021
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
Boehringer Ingelheim launches University of Medicine Excellence
By IPP Bureau - October 12, 2021
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Glenmark launches Tavulus for COPD treatment in Spain
By IPP Bureau - October 11, 2021
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Deep Lens and Pacific Cancer Centre collaborate to improve clinical trials
By IPP Bureau - October 11, 2021
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
Astra’s antibody injection trial indicates it can prevent and treat Covid-19
By IPP Bureau - October 11, 2021
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
IDFC FIRST Bank & Banyan Academy launch Centre for Trauma Studies & Innovation
By IPP Bureau - October 11, 2021
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
HealthEdge opens its facility in Pune
By IPP Bureau - October 11, 2021
The Pune centre expands its presence beyond Bangalore and Hyderabad
Kaneka Covid-19 kits detect all four variants simultaneously
By IPP Bureau - October 11, 2021
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
By IPP Bureau - October 11, 2021
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Sai Life Sciences presents its midterm report
By IPP Bureau - October 11, 2021
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
AstraZeneca India launches solar project to achieve sustainability goals
By IPP Bureau - October 11, 2021
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Gland Pharma receives tentative nod for Sugammadex injection
By IPP Bureau - October 09, 2021
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
Cyprium Therapeutics and Sentynl, a Zydus subsidiary announce positive data for CUTX-101, CuHis
By IPP Bureau - October 09, 2021
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
